Loading clinical trials...

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder | Clinical Trials | Clareo Health

COMPLETEDPHASE4

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder

NCT00044187•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine. The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Eligibility Criteria:
•You must be between the ages of 18 and 65. If you have reached your 66th birthday, you will not be able to participate.
•You must have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar I disorder and be taking olanzapine.
•You must be able to visit the doctor's office as scheduled for the next 4 months.

Exclusion Criteria

•You have a history of an illness that would cause weight loss or gain in the near future.
•You have taken remoxipride within the past 6 months.
•You are allergic to olanzapine or Anti-obesity Agent.
•You have uncontrolled high blood pressure, congestive heart failure, or have had a stroke.
•You have a serious medical illness, such as heart, liver, or kidney disease.
•You are pregnant or breast feeding.

Locations (16)

El Centro, California, United States

Jacksonville, Florida, United States

Miami, Florida, United States

Boise, Idaho, United States

Chicago, Illinois, United States

Indianapolis, Indiana, United States

Lafayette, Indiana, United States

Prairie Village, Kansas, United States

Milford, Massachusetts, United States

Clementon, New Jersey, United States

Key Dates

Start Date

April 1, 2001

Completion Date

September 1, 2003

Last Updated

July 19, 2006

Enrollment

130

Estimated participants

Conditions

SchizophreniaPsychotic DisordersBipolar Disorder

Interventions

Sibutramine

DRUG

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

NCT07455929

Psychotic DisordersSchizophrenia Spectrum Disorders

View study

RECRUITINGNA

Racial Disparities in the Expression of Paranoia

NCT07460453

ParanoiaPsychotic Disorders

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 19, 2006Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

Inclusion Criteria

Exclusion Criteria

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Racial Disparities in the Expression of Paranoia

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

University of Iowa Interventional Psychiatry Service Patient Registry